Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1617sxw

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4	Apr 09	ZDB will be removed from STN
NEWS 5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 9	Jun 03	New e-mail delivery for search results now available
NEWS 10	Jun 10	MEDLINE Reload
NEWS 11	Jun 10	PCTFULL has been reloaded
NEWS 12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS 13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS 14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS 15	Jul 30	NETFIRST to be removed from STN
NEWS 16	Aug 08	CANCERLIT reload
NEWS 17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18	Aug 08	NTIS has been reloaded and enhanced
NEWS 19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 23	Sep 03	JAPIO has been reloaded and enhanced
NEWS 24	Sep 16	Experimental properties added to the REGISTRY file
NEWS 25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27	Oct 21	EVENTLINE has been reloaded
NEWS 28	Oct 24	BEILSTEIN adds new search fields
NEWS 29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS 31	Nov 18	DKILIT has been renamed APOLLIT
NEWS 32	Nov 25	More calculated properties added to REGISTRY
NEWS 33	Dec 02	TIBKAT will be removed from STN
NEWS 34	Dec 04	CSA files on STN
NEWS 35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 36	Dec 17	TOXCENTER enhanced with additional content
NEWS 37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 38	Dec 30	ISMEC no longer available
NEWS 39	Jan 21	NUTRACEUT offering one free connect hour in February 2003
NEWS 40	Jan 21	PHARMAML offering one free connect hour in February 2003
NEWS 41	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 42	Feb 13	CANCERLIT is no longer being updated
NEWS 43	Feb 24	METADEX enhancements
NEWS 44	Feb 24	PCTGEN now available on STN
NEWS 45	Feb 24	TEMA now available on STN
NEWS 46	Feb 26	NTIS now allows simultaneous left and right truncation

```
NEWS 47   Feb 26   PCTFULL now contains images
NEWS 48   Mar 04   SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 49   Mar 19   APOLLIT offering free connect time in April 2003
NEWS 50   Mar 20   EVENTLINE will be removed from STN
NEWS 51   Mar 24   PATDPAFULL now available on STN
NEWS 52   Mar 24   Additional information for trade-named substances without
                   structures available in REGISTRY
NEWS 53   Mar 24   Indexing from 1957 to 1966 added to records in CA/CAPLUS

NEWS EXPRESS  January 6 CURRENT WINDOWS VERSION IS V6.01a,
              CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
              AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS    STN Operating Hours Plus Help Desk Availability
NEWS INTER    General Internet Information
NEWS LOGIN    Welcome Banner and News Items
NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *



FILE 'HOME' ENTERED AT 18:21:42 ON 31 MAR 2003

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 18:22:27 ON 31 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   30 MAR 2003  HIGHEST RN 500991-80-0
DICTIONARY FILE UPDATES:  30 MAR 2003  HIGHEST RN 500991-80-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 09981025.str
```

```
L1      STRUCTURE UPLOADED

=> s l1 sss sam
SAMPLE SEARCH INITIATED 18:22:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     12 TO ITERATE

100.0% PROCESSED      12 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           33 TO      447
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=>
Uploading 09981025b.str

L3      STRUCTURE UPLOADED

=> s l3 sss sam
SAMPLE SEARCH INITIATED 18:28:51 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     12 TO ITERATE

100.0% PROCESSED      12 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           33 TO      447
PROJECTED ANSWERS:               0 TO        0

L4            0 SEA SSS SAM L3

=> s l3 sss ful
FULL SEARCH INITIATED 18:29:14 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    249 TO ITERATE

100.0% PROCESSED     249 ITERATIONS                               34 ANSWERS
SEARCH TIME: 00.00.01

L5           34 SEA SSS FUL L3

=> d 1-34

L5   ANSWER 1 OF 34  REGISTRY  COPYRIGHT 2003 ACS
RN   457911-01-2  REGISTRY
CN   1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(3-
     hydroxypropyl)methylamino]-N-methyl-.alpha.-phenyl-, (2E)-2-butenedioate
     (2:1) (salt) (9CI)  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C28 H35 F6 N3 O2 . 1/2 C4 H4 O4
SR   CA
LC   STN Files:   CA, CAPLUS

     CM   1

     CRN  415916-92-6
     CMF  C28 H35 F6 N3 O2
```



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 2 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 457910-98-4 REGISTRY
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(cyclopropylmethyl)methylamino]-N-methyl-.alpha.-phenyl-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H35 F6 N3 O . 1/2 C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 415917-00-9
CMF C29 H35 F6 N3 O



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 3 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 457910-81-5 REGISTRY
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(cyclopropylmethyl)(3-hydroxypropyl)amino]-N-methyl-.alpha.-phenyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C31 H39 F6 N3 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 4 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 457910-79-1 REGISTRY
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(2-hydroxyethyl)(3-hydroxypropyl)amino]-N-methyl-.alpha.-phenyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C29 H37 F6 N3 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 5 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 415917-13-4 REGISTRY
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-N-methyl-.alpha.-phenyl-, (.alpha.S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H33 F6 N3 O3

SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1962 TO DATE)
3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 6 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 415917-12-3 REGISTRY
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(3-hydroxypropyl)methylamino]-N-methyl-.alpha.-phenyl-, (.alpha.S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H35 F6 N3 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 7 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 415917-11-2 REGISTRY
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(cyclopropylmethyl)methylamino]-N-methyl-.alpha.-phenyl-, (.alpha.S)-(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H35 F6 N3 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 8 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 415917-07-6 REGISTRY
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(cyclopropylmethyl)(3-hydroxypropyl)amino]-N-methyl-.alpha.-phenyl-, (.alpha.S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H39 F6 N3 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1962 TO DATE)
3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 9 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 415917-04-3 REGISTRY
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(2-hydroxyethyl)(3-hydroxypropyl)amino]-N-methyl-.alpha.-phenyl-, (.alpha.S)-(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H37 F6 N3 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 10 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 415917-01-0 REGISTRY
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(cyclopropylmethyl)methylamino]-N-methyl-.alpha.-phenyl-, compd. with (2E)-2-butene (2:3) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H35 F6 N3 O . 3/2 C4 H8
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 415917-00-9
CMF C29 H35 F6 N3 O



CM 2

CRN 624-64-6
CMF C4 H8

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 11 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 415917-00-9 REGISTRY
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(cyclopropylmethyl)methylamino]-N-methyl-.alpha.-phenyl- (9CI) (CA INDEX NAME)
OTHER NAMES:

CN BIIM 1310
FS 3D CONCORD
MF C29 H35 F6 N3 O
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 12 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 415916-97-1 REGISTRY
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-N-methyl-.alpha.-phenyl-, monomethanesulfonate (salt) (9CI) (CA INDEX NAME)
MF C27 H33 F6 N3 O3 . C H4 O3 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 415916-96-0
CMF C27 H33 F6 N3 O3



CM 2

CRN 75-75-2
CMF C H4 O3 S



2 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 13 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 415916-96-0 REGISTRY
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-N-methyl-.alpha.-phenyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C27 H33 F6 N3 O3
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 14 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 415916-93-7 REGISTRY
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(3-hydroxypropyl)methylamino]-N-methyl-.alpha.-phenyl-, compd. with (2E)-2-butene (2:3) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H35 F6 N3 O2 . 3/2 C4 H8
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 415916-92-6
CMF C28 H35 F6 N3 O2



CM 2

CRN 624-64-6
CMF C4 H8

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 15 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 415916-92-6 REGISTRY
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(3-hydroxypropyl)methylamino]-N-methyl-.alpha.-phenyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C28 H35 F6 N3 O2
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 16 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 414904-23-7 REGISTRY
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[[[(4-methoxyphenyl)amino]carbonyl]amino]-N-methyl-.alpha.-phenyl-, (.alpha.S)-(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C32 H34 F6 N4 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 17 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 414904-22-6 REGISTRY
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-N-methyl-4-[[(methylamino)carbonyl]amino]-.alpha.-phenyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C26 H30 F6 N4 O2
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 18 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 414904-21-5 REGISTRY
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-N-methyl-.alpha.-phenyl-4-[[(phenylamino)carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H32 F6 N4 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 19 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 414904-15-7 REGISTRY
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-N-methyl-4-[[(methylamino)carbonyl]amino]-.alpha.-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)
MF C26 H30 F6 N4 O2 . Cl H

SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (414904-22-6)



● HCl

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 20 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 196818-34-5 REGISTRY
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(4-hydroxybutyl)methylamino]-N-methyl-.alpha.-phenyl-, (2E)-2-butenedioate (1:2) (salt) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(4-hydroxybutyl)methylamino]-N-methyl-.alpha.-phenyl-, (E)-2-butenedioate (1:2) (salt)
FS STEREOSEARCH
MF C29 H37 F6 N3 O2 . 2 C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 196818-33-4
CMF C29 H37 F6 N3 O2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 21 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 196818-33-4 REGISTRY
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(4-hydroxybutyl)methylamino]-N-methyl-.alpha.-phenyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C29 H37 F6 N3 O2
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 22 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 196818-16-3 REGISTRY
CN 1-Piperidineacetamide, 4-[bis(2-hydroxyethyl)amino]-N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-N-methyl-.alpha.-phenyl-, (2E)-2-butenedioate (1:2) (salt) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1-Piperidineacetamide, 4-[bis(2-hydroxyethyl)amino]-N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-N-methyl-.alpha.-phenyl-, (E)-2-butenedioate (1:2) (salt)
FS STEREOSEARCH
MF C28 H35 F6 N3 O3 . 2 C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 196818-15-2
CMF C28 H35 F6 N3 O3



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 23 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 196818-15-2 REGISTRY
CN 1-Piperidineacetamide, 4-[bis(2-hydroxyethyl)amino]-N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-N-methyl-.alpha.-phenyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C28 H35 F6 N3 O3
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 24 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 196817-98-8 REGISTRY
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-N-methyl-4-[[2-(4-morpholinyl)-2-oxoethyl]amino]-.alpha.-phenyl-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-N-methyl-4-[[2-(4-morpholinyl)-2-oxoethyl]amino]-.alpha.-phenyl-, (E)-2-butenedioate (1:2)
FS STEREOSEARCH
MF C30 H36 F6 N4 O3 . 2 C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 196817-97-7
CMF C30 H36 F6 N4 O3



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 25 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 196817-97-7 REGISTRY
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-N-methyl-4-[[2-(4-morpholinyl)-2-oxoethyl]amino]-.alpha.-phenyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C30 H36 F6 N4 O3
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 26 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 196817-94-4 REGISTRY
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-N-methyl-4-[(1-methylethyl)amino]-.alpha.-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)
MF C27 H33 F6 N3 O . 2 Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



●2 HCl

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 27 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 196817-93-3 REGISTRY
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-(cyclopentylamino)-N-methyl-.alpha.-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)
MF C29 H35 F6 N3 O . 2 Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



●2 HCl

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 28 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 196817-92-2 REGISTRY
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-N-methyl-4-(methylamino)-.alpha.-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)
MF C25 H29 F6 N3 O . 2 Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



2 HCl

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 29 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 196817-91-1 REGISTRY
CN 1-Piperidineacetamide, 4-amino-N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-N-methyl-.alpha.-phenyl-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1-Piperidineacetamide, 4-amino-N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-N-methyl-.alpha.-phenyl-, (E)-2-butenedioate (1:2)
FS STEREOSEARCH
MF C24 H27 F6 N3 O . 2 C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 196817-90-0
CMF C24 H27 F6 N3 O



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 30 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 196817-90-0 REGISTRY
CN 1-Piperidineacetamide, 4-amino-N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-N-methyl-.alpha.-phenyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H27 F6 N3 O
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 31 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 196817-89-7 REGISTRY
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(2-hydroxyethyl)methylamino]-N-methyl-.alpha.-phenyl-, (2E)-2-butenedioate (1:2) (salt) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(2-hydroxyethyl)methylamino]-N-methyl-.alpha.-phenyl-, (E)-2-butenedioate (1:2) (salt)
FS STEREOSEARCH
MF C27 H33 F6 N3 O2 . 2 C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 196817-88-6
CMF C27 H33 F6 N3 O2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 32 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 196817-88-6 REGISTRY
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(2-hydroxyethyl)methylamino]-N-methyl-.alpha.-phenyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C27 H33 F6 N3 O2
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 33 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 196817-87-5 REGISTRY
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-(diethylamino)-N-methyl-.alpha.-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)
MF C28 H35 F6 N3 O . 2 Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



●2 HCl

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 34 OF 34 REGISTRY COPYRIGHT 2003 ACS
RN 196817-79-5 REGISTRY
CN 1-Piperidineacetamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-(dimethylamino)-N-methyl-.alpha.-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)
MF C26 H31 F6 N3 O . 2 Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



●2 HCl

1 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	210.47	210.68

FILE 'CAPLUS' ENTERED AT 18:30:45 ON 31 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 31 Mar 2003 VOL 138 ISS 14
FILE LAST UPDATED: 30 Mar 2003 (20030330/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l5
L6 5 L5

=> d ibib abs 1-5

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:869585 CAPLUS
DOCUMENT NUMBER: 137:346202
TITLE: Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists for the treatment of respiratory tract diseases
INVENTOR(S): Pairet, Michel; Pieper, Michael P.; Meade, Christopher J. M.
PATENT ASSIGNEE(S): Germany
SOURCE: U.S. Pat. Appl. Publ., 18 pp., Cont.-in-part of U. S. Provisional Ser. NO. 281,653.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002169181	A1	20021114	US 2002-92116	20020306
DE 10111058	A1	20020912	DE 2001-10111058	20010308
PRIORITY APPLN. INFO.:			DE 2001-10111058 A	20010308
			US 2001-281653P P	20010405

OTHER SOURCE(S): MARPAT 137:346202
AB The invention discloses pharmaceutical compns. based on anticholinergics and NK1-receptor antagonists, processes for prepg. them, and their use in the treatment of respiratory tract diseases. Prepn. of selected compds. is included.

L6 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:695760 CAPLUS
DOCUMENT NUMBER: 137:237717
TITLE: Inhalant compositions containing anticholinergics and NK1 receptor antagonists
INVENTOR(S): Meade, Christopher John Montague; Pairet, Michel; Pieper, Michael Paul
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069944	A2	20020912	WO 2002-EP1987	20020226
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10111058	A1	20020912	DE 2001-10111058	20010308

PRIORITY APPLN. INFO.: DE 2001-10111058 A 20010308
OTHER SOURCE(S): MARPAT 137:237717
AB The invention relates to drug compns. based on anticholinergics and on NK1 receptor antagonists, to methods for their prodn., and to their use as inhalants for the treatment of respiratory tract diseases. Synthesis of NK1 receptor antagonists from the group of bis-trifluoromethyl-phenyl-piperidine derivs. are described. The products are used in suspension aerosols. Thus a compn. contained (wt./wt.%): tiotropium bromide 0.015; NK1 receptor antagonist 0.066; soy lecithin 0.2; TG11: TG12 = 2:3 to 100.

L6 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:314908 CAPLUS
DOCUMENT NUMBER: 136:340591
TITLE: Preparation of carboxamidopiperidine-1-acetamides as neurokinin NK1 receptor antagonists
INVENTOR(S): Dollinger, Horst; Esser, Franz; Jung, Birgit; Schnorrenberg, Gerd; Schromm, Kurt; Speck, Georg
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032866	A1	20020425	WO 2001-EP11907	20011016
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				

BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10051321	A1	20020425	DE 2000-10051321	20001017
AU 2002010537	A5	20020429	AU 2002-10537	20011016
US 2002115666	A1	20020822	US 2001-978639	20011016

PRIORITY APPLN. INFO.: DE 2000-10051321 A 20001017
US 2000-250660P P 20001201
WO 2001-EP11907 W 20011016

OTHER SOURCE(S): MARPAT 136:340591

AB R1Z1CONR2ZCHRCONR3R4 (Z = piperidine-1,4-diyl)[I; R1 = alkyl or (un)substituted Ph; R2 = H, alkyl, cycloalkylmethyl; R1R2 = (oxo)alkylene; R3 = CH2CH2R5; R4 = H, alkyl, Ph, etc.; R5 = (un)substituted Ph; Z1 = O or (alkyl)imino] were prepd. Thus, 4-(3-methylureido)piperidine was N-alkylated by MeSO2OCHPhCONMeCH2CH2C6H3(CF3)2-3,5 to give I [R = Ph, R1 = R4 = Me, R2 = H, R3 = CH2CH2C6H3(CF3)2-3,5, Z1 = NH]. Data for biol. activity of I were given.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:314907 CAPLUS
DOCUMENT NUMBER: 136:340590
TITLE: 4-Aminopiperidinylacetamides as neurokinin antagonists
INVENTOR(S): Dollinger, Horst; Esser, Franz; Jung, Birgit; Schromm, Kurt; Speck, Georg
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032865	A1	20020425	WO 2001-EP11906	20011016

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10051320	A1	20020425	DE 2000-10051320	20001017
AU 2002023617	A5	20020429	AU 2002-23617	20011016
US 2002147219	A1	20021010	US 2001-981025	20011016

PRIORITY APPLN. INFO.: DE 2000-10051320 A 20001017
US 2000-250541P P 20001201
WO 2001-EP11906 W 20011016

OTHER SOURCE(S): MARPAT 136:340590

GI



I

AB Title compds. I [R1 = (CH2)3OH, CH2CH(OH)CH2OH, cycloalkylmethyl; R2 = H, alkyl, hydroxyalkyl, CH2CH(OH)CH2OH, cycloalkylmethyl; R3 = (un)substituted Ph; R4 = H, alkyl, cycloalkyl, CH2CO2H, CH2CONH2. OH,

phenylalkyl; Ar = (un)substituted Ph] were prepd. Thus, 1-benzyl-4-piperidinone was treated with H2N(CH2)3OH, N-methylated, debenzylated, and treated with 3,5-(F3C)2C6H3CH2CH2NMeCOCHPhO3SMe to give I [R1 = (CH2)3OH, R2 = R3 = Me, R4 = 3,5-(F3C)2C6H3CH2CH2]. At 0.2 .mu.Mol/kg iv in guinea pigs this compd. was effective in lowering blood pressure for > 360 min.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:618085 CAPLUS

DOCUMENT NUMBER: 127:278211

TITLE: Novel arylglycinamide derivatives, processes for their preparation, and pharmaceutical compositions containing them as neurokinin antagonists

INVENTOR(S): Esser, Franz; Schnorrenberg, Gerd; Schromm, Kurt; Dollinger, Horst; Jung, Birgit; Speck, Georg

PATENT ASSIGNEE(S): Boehringer Ingelheim K.-G., Germany; Esser, Franz; Schnorrenberg, Gerd; Schromm, Kurt; Dollinger, Horst; Jung, Birgit; Speck, Georg

SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9732865	A1	19970912	WO 1997-EP1038	19970303
W: AU, BG, BR, BY, CA, CN, CZ, EE, HU, IL, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
DE 19608665	A1	19970911	DE 1996-19608665	19960306
CA 2247257	AA	19970912	CA 1997-2247257	19970303
AU 9720943	A1	19970922	AU 1997-20943	19970303
AU 718584	B2	20000413		
EP 885204	A1	19981223	EP 1997-906150	19970303
EP 885204	B1	20020612		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1212689	A	19990331	CN 1997-192786	19970303
CN 1072664	B	20011010		
BR 9708014	A	19990727	BR 1997-8014	19970303
NZ 332201	A	20000128	NZ 1997-332201	19970303
JP 2000506150	T2	20000523	JP 1997-531438	19970303
AT 219069	E	20020615	AT 1997-906150	19970303
EE 3767	B1	20020617	EE 1998-302	19970303
ES 2177940	T3	20021216	ES 1997-906150	19970303
ZA 9701850	A	19970908	ZA 1997-1850	19970304
NO 9804080	A	19980904	NO 1998-4080	19980904
US 6498162	B1	20021224	US 2000-703758	20001101

PRIORITY APPLN. INFO.: DE 1996-19608665 A 19960306
WO 1997-EP1038 W 19970303
US 1998-142271 B1 19981130

OTHER SOURCE(S): MARPAT 127:278211

GI



II

AB The invention relates to novel arylglycinamide derivs. R1R2NCR3(Ar)CONR4R5 I and their pharmaceutically acceptable salts [in which Ar = (un)substituted Ph or naphthyl, 1,3-benzodioxolyl, 1,4-benzopyranyl; NR1R2 = certain N-heterocycles; R3 = H, alkyl, (un)substituted Ph; R4 = (un)substituted phenylalkyl, naphthylalkyl; R5 = H, alkyl, cycloalkyl, CH2CO2H, CH2CONH2, OH, phenylalkyl]. Also disclosed are the prodn. and use of I, which are valuable neurokinin (tachykinin) antagonists. For example, 1-isopropylpiperazine underwent N-alkylation by PhCHBrCO2Me (89%), followed by sapon. of the ester (92%) and amidation of the resultant acid with N-methyl-3,5-bis(trifluoromethyl)phenethylamine (75%), to give title compd. II, isolated as the di-HCl salt. At 1 mg/kg intraduodenally in anesthetized guinea pigs, II.2HCl gave an 80% reversal of NK1-agonist-induced hypotension.

=> d index 1
'INDEX' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers; SCAN must be entered on the same line as the DISPLAY, e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, IPC, and NCL

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations

SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT) containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):ind

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS
IC ICM A61K031-4745
NCL 514291000
CC 1-9 (Pharmacology)
Section cross-reference(s): 27, 63
ST anticholinergic NK1 receptor antagonist prepn respiratory disease
IT Tachykinin receptors
(NK1 antagonists; anticholinergics and NK1-receptor antagonists for treatment of respiratory tract diseases)
IT Drug delivery systems
(aerosols; anticholinergics and NK1-receptor antagonists for treatment of respiratory tract diseases)
IT Cholinergic antagonists
Drug delivery systems
(anticholinergics and NK1-receptor antagonists for treatment of respiratory tract diseases)
IT Drug delivery systems
(inhalants; anticholinergics and NK1-receptor antagonists for treatment of respiratory tract diseases)
IT 147116-64-1, CJ 11974
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CJ 11974; anticholinergics and NK1-receptor antagonists for treatment of respiratory tract diseases)
IT 178370-50-8, MDL 103896
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MDL 103896; anticholinergics and NK1-receptor antagonists for treatment of respiratory tract diseases)
IT 173941-22-5, YM 35375
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(YM 35375; anticholinergics and NK1-receptor antagonists for treatment of respiratory tract diseases)
IT 173941-74-7, YM 44778
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(YM 44778; anticholinergics and NK1-receptor antagonists for treatment of respiratory tract diseases)

IT 173941-19-0, YM 49244
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(YM 49244; anticholinergics and NK1-receptor antagonists for treatment of respiratory tract diseases)

IT 136310-93-5, Tiotropium bromide
RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(anticholinergics and NK1-receptor antagonists for treatment of respiratory tract diseases)

IT 411207-31-3P, Tiotropium bromide monohydrate **415916-92-6P** **415916-96-0P** **415917-00-9P** **415917-07-6P** **457910-79-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(anticholinergics and NK1-receptor antagonists for treatment of respiratory tract diseases)

IT 598-41-4D, Glycinamide, aryl derivs. 60205-81-4D, Ipratropium, salts 99571-64-9D, Oxitropium, salts 138449-07-7, FK-888 142001-63-6, Saredutant 145742-28-5, CP-122721 155418-06-7 168266-90-8, GR 205171 170566-84-4, Lanepitant 170729-80-3, MK-869 171272-39-2, MEN-10930 172673-20-0, L-758298 174636-32-9, SB 223412 174661-97-3, DA-5018 183747-35-5, Nepadutant 186691-13-4D, Tiotropium, salts 188241-50-1, S-19752 193694-35-8, MDL-105172A 201152-86-5, SR-144190 206052-25-7, MEN-11149 209474-01-1, Neuronorm 214487-46-4, MEN-11467 217185-75-6, TAK-637 350610-25-2, BIIF 1149 350610-26-3, 6b-I 350610-27-4, DNK-33A 350610-29-6, ZM-274773 350610-34-3, DNK 333A 350610-51-4, CGP 60829 350610-61-6, NKP 608A 350610-64-9, NKP 608C **415917-13-4** **457910-81-5**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anticholinergics and NK1-receptor antagonists for treatment of respiratory tract diseases)

IT 156-87-6, 3-Aminopropanol 534-03-2 1489-69-6, Cyclopropanecarboxaldehyde 3612-20-2, 1-Benzyl-4-piperidone 7006-50-0, 1-Benzyl-4-methylaminopiperidine 19344-29-7 251292-11-2 414904-26-0 415916-89-1 415917-03-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(anticholinergics and NK1-receptor antagonists for treatment of respiratory tract diseases)

IT 198823-22-2P 415916-90-4P 415916-91-5P 415916-94-8P 415916-95-9P 415916-98-2P 415916-99-3P 415917-05-4P 415917-06-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(anticholinergics and NK1-receptor antagonists for treatment of respiratory tract diseases)

IT 415917-02-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(anticholinergics and NK1-receptor antagonists for treatment of respiratory tract diseases)

=> d ind 2-5

L6 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS
IC ICM A61K031-00
CC 63-6 (Pharmaceuticals)
ST inhalant anticholinergics tiotropium NK1 receptor antagonist
IT Tachykinin receptors
(NK1 antagonists; inhalant compns. contg. anticholinergics and NK1 receptor antagonists)

IT Drug delivery systems
(aerosols; inhalant compns. contg. anticholinergics and NK1 receptor antagonists)
IT Polyoxyalkylenes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alcs. and fatty acid esters; inhalant compns. contg. anticholinergics and NK1 receptor antagonists)
IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylbenzyldimethyl, chlorides; inhalant compns. contg. anticholinergics and NK1 receptor antagonists)
IT Lung, disease
(chronic obstructive; inhalant compns. contg. anticholinergics and NK1 receptor antagonists)
IT Solvents
(cosolvents; inhalant compns. contg. anticholinergics and NK1 receptor antagonists)
IT Respiratory tract
(disease; inhalant compns. contg. anticholinergics and NK1 receptor antagonists)
IT Glycols, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ethers; inhalant compns. contg. anticholinergics and NK1 receptor antagonists)
IT Ethers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(glycol; inhalant compns. contg. anticholinergics and NK1 receptor antagonists)
IT Hydrocarbons, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(halo; inhalant compns. contg. anticholinergics and NK1 receptor antagonists)
IT Antioxidants
Cholinergic antagonists
Complexing agents
Enantiomers
Flavor
Lubricants
Particle size
Preservatives
Propellants (sprays and foams)
Solvents
Stabilizing agents
Surfactants
(inhalant compns. contg. anticholinergics and NK1 receptor antagonists)
IT Disaccharides
Glycols, biological studies
Monosaccharides
Oligosaccharides, biological studies
Polyoxyalkylenes, biological studies
Polysaccharides, biological studies
Tocopherols
Vitamins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhalant compns. contg. anticholinergics and NK1 receptor antagonists)
IT Drug delivery systems
(inhalants; inhalant compns. contg. anticholinergics and NK1 receptor antagonists)
IT Medical goods
(inhalers; inhalant compns. contg. anticholinergics and NK1 receptor antagonists)
IT Alcohols, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyhydric; inhalant compns. contg. anticholinergics and NK1 receptor antagonists)

IT Drug delivery systems
(suspensions; inhalant compns. contg. anticholinergics and NK1 receptor antagonists)

IT 7732-18-5, Water, properties
RL: PRP (Properties)
(casreact)

IT 63-42-3, Lactose 136310-93-5, Tiotropium bromide 411207-31-3, Tiotropium bromide monohydrate
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(inhalant compns. contg. anticholinergics and NK1 receptor antagonists)

IT 156-87-6, 3-Aminopropanol 534-03-2, 2-Aminopropane-1,3-diol 1489-69-6, Cyclopropanecarboxaldehyde 3612-20-2, 1-Benzyl-4-piperidone 251292-11-2 414904-26-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(inhalant compns. contg. anticholinergics and NK1 receptor antagonists)

IT 7006-50-0P, 1-Benzyl-4-methylaminopiperidine 198823-22-2P 415916-89-1P 415916-90-4P 415916-91-5P 415916-94-8P 415916-95-9P 415916-98-2P 415916-99-3P 415917-02-1P 415917-03-2P 415917-05-4P 415917-06-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(inhalant compns. contg. anticholinergics and NK1 receptor antagonists)

IT **415916-92-6P 415916-96-0P 415916-97-1P 415917-00-9P**, BIIM 1310 **415917-07-6P 457910-79-1P 457910-98-4P 457911-01-2P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inhalant compns. contg. anticholinergics and NK1 receptor antagonists)

IT 50-81-7, Ascorbic acid, biological studies 56-81-5, Glycerol, biological studies 57-55-6, Propylene glycol, biological studies 64-02-8 64-17-5, Ethanol, biological studies 64-18-6, Formic acid, biological studies 64-19-7, Acetic acid, biological studies 65-85-0, Benzoic acid, biological studies 74-98-6, n-Propane, biological studies 75-28-5, Isobutane 77-92-9, Citric acid, biological studies 79-09-4, Propionic acid, biological studies 106-97-8, n-Butane, biological studies 110-15-6, Succinic acid, biological studies 110-16-7, Maleic acid, biological studies 110-17-8, Fumaric acid, biological studies 123-03-5, Cetylpyridinium chloride 431-89-0, TG227 526-83-0, Tartaric acid 811-97-2, TG134a 1406-18-4, Vitamin E 6915-15-7, Malic acid 7647-01-0, Hydrochloric acid, biological studies 7664-93-9, Sulfuric acid, biological studies 7697-37-2, Nitric acid, biological studies 10035-10-6, Hydrobromic acid, biological studies 11103-57-4, Vitamin A 25322-68-3, Polyethylene glycol 25322-68-3D, alcs. and fatty acid esters 25322-69-4, Polypropylene glycol 60205-81-4, Ipratropium 99571-64-9, Oxitropium 138449-07-7, FK-888 142001-63-6, Saredutant 145742-28-5, CP-122721 147116-64-1, CJ 11974 155418-05-6, SR 140333 168266-90-8, GR 205171 170566-84-4, Lanepitant 170729-80-3, MK-869 171272-39-2, MEN-10930 172673-20-0, L-758298 173941-19-0, YM 49244 173941-22-5, YM 35375 173941-74-7, YM 44778 174636-32-9, SB 223412 174661-97-3, DA-5018 178370-50-8, MDL 103896 183747-35-5, Nepadutant 188241-50-1, S-19752 193694-35-8, MDL-105172A 201152-86-5, SR-144190 206052-25-7, MEN-11149 209474-01-1, Neuronorm 214487-46-4, MEN-11467 217185-75-6, TAK-637 350610-25-2 350610-26-3, 6b-I 350610-27-4, DNK-33A 350610-29-6, ZM-274773 350610-34-3, DNK 333A 350610-51-4, CGP 60829 350610-61-6, NKP 608A 350610-64-9, NKP 608C **415917-13-4 457910-81-5** 458568-84-8, TG 11 458569-01-2, TG 12
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhalant compns. contg. anticholinergics and NK1 receptor antagonists)

L6 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS

IC ICM C07D211-58
ICS A61P011-06; A61P027-14; A61P029-00; A61P025-00; C07D401-12; C07D413-12; A61K031-495; A61P037-08

CC 27-16 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 1
ST carboxamidopiperidineacetamide prepn neurokinin NK1 receptor antagonist
IT Neurokinins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(mediated disorders; treatment; prepn. of carboxamidopiperidine-1-acetamides as neurokinin NK1 receptor antagonists)
IT Tachykinin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type NK1, mediated disorders; treatment; prepn. of carboxamidopiperidine-1-acetamides as neurokinin NK1 receptor antagonists)
IT **414904-15-7P** 414904-16-8P 414904-17-9P 414904-18-0P
414904-19-1P 414904-20-4P **414904-21-5P 414904-22-6P**
414904-23-7P 414904-24-8P 414904-25-9P 415920-89-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of carboxamidopiperidine-1-acetamides as neurokinin NK1 receptor antagonists)
IT 58083-18-4 164518-99-4 251292-11-2 414904-26-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of carboxamidopiperidine-1-acetamides as neurokinin NK1 receptor antagonists)

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS
IC ICM C07D211-58
ICS A61K031-4468; A61P009-02
CC 27-16 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1
ST aminopiperidinylacetamide prepn neurokinin antagonist
IT Neurokinins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; prepn. of 4-aminopiperidinylacetamides as neurokinin antagonists)
IT Antihypertensives
(prepn. of 4-aminopiperidinylacetamides as neurokinin antagonists)
IT **415916-93-7P 415916-97-1P 415917-01-0P**
415917-04-3P 415917-07-6P 415917-08-7P 415917-09-8P
415917-10-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 4-aminopiperidinylacetamides as neurokinin antagonists)
IT 156-87-6, 3-Amino-1-propanol 534-03-2, 2-Amino-1,3-propanediol
1489-69-6, Cyclopropanecarboxaldehyde 3612-20-2, 1-Benzyl-4-piperidinone
19344-29-7 251292-11-2 414904-26-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of 4-aminopiperidinylacetamides as neurokinin antagonists)
IT 7006-50-0P 198823-22-2P 415916-89-1P 415916-90-4P 415916-91-5P
415916-94-8P 415916-95-9P 415916-98-2P 415916-99-3P 415917-02-1P
415917-03-2P 415917-05-4P 415917-06-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 4-aminopiperidinylacetamides as neurokinin antagonists)
IT **415917-11-2P 415917-12-3P 415917-13-4P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 4-aminopiperidinylacetamides as neurokinin antagonists)

L6 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS
IC ICM C07D295-14
ICS C07D213-74; C07D317-60
CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 34
ST arylglycinamide prepn neurokinin tachykinin antagonist; glycinamide aryl

prepn neurokinin tachykinin antagonist

IT Tachykinin receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(NK1; prepn. of arylglycinamide derivs. as neurokinin antagonists)

IT Drugs
(gastrointestinal; prepn. of arylglycinamide derivs. as neurokinin antagonists)

IT Allergy inhibitors
Anti-inflammatory agents
Antiasthmatics
Nervous system agents
(prepn. of arylglycinamide derivs. as neurokinin antagonists)

IT Neurokinins
Tachykinins
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(prepn. of arylglycinamide derivs. as neurokinin antagonists)

IT Eye, disease
Skin, disease
(treatment; prepn. of arylglycinamide derivs. as neurokinin antagonists)

IT 196818-37-8P 196818-39-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of arylglycinamide derivs. as neurokinin antagonists)

IT 196817-75-1P 196817-76-2P 196817-77-3P 196817-78-4P
196817-79-5P 196817-80-8P 196817-81-9P 196817-82-0P
196817-83-1P 196817-84-2P 196817-85-3P 196817-86-4P
196817-87-5P **196817-89-7P** **196817-91-1P**
196817-92-2P **196817-93-3P** **196817-94-4P**
196817-96-6P **196817-98-8P** 196817-99-9P 196818-02-7P
196818-03-8P 196818-04-9P 196818-05-0P 196818-07-2P 196818-09-4P
196818-11-8P 196818-13-0P **196818-16-3P** 196818-18-5P
196818-20-9P 196818-22-1P 196818-23-2P 196818-25-4P 196818-27-6P
196818-29-8P 196818-31-2P **196818-34-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of arylglycinamide derivs. as neurokinin antagonists)

IT 33507-63-0, Substance P
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(prepn. of arylglycinamide derivs. as neurokinin antagonists)

IT 3042-81-7 4318-42-7 196818-41-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; prepn. of arylglycinamide derivs. as neurokinin antagonists)

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	18.18	228.86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.26	-3.26

STN INTERNATIONAL LOGOFF AT 18:37:06 ON 31 MAR 2003